United Therapeutics Wins Unituxin Approval, Pediatric Priority Review Voucher – With NIH Support
This article was originally published in The Pink Sheet Daily
The National Cancer Institute conducted the clinical trials of Unituxin for treatment of pediatric high-risk neuroblastoma and teamed with United for manufacturing and commercialization.
You may also be interested in...
Advisory committee supports further research on end-of-induction response as an early interim clinical endpoint for drugs in treatment of high-risk neuroblastoma. FDA has approved two drugs for this rare disease in children, who have a 40-50% chance of long-term survival.
With partner Genentech, AbbVie is planning to file the BCL-2 inhibitor for US and EU approval in tough-to-treat CLL later this year on the back of promising Phase II data.
Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.